United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Down 1.5%

UTHR stock traded down $7.88 during mid-day trading on Friday, reaching $513.12. The company had a trading volume of 414,570 shares, compared to its average volume of 490,770. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The stock has a market capitalization of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.79 and a beta of 0.59. The stock’s 50-day simple moving average is $533.74 and its two-hundred day simple moving average is $537.53.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the firm earned $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the period. Jump Financial LLC acquired a new position in United Therapeutics during the second quarter worth about $277,000. Cerity Partners LLC raised its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia lifted its holdings in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.